Daniel Grau, Avilar Therapeutics CEO

Ex­clu­sive: Sanofi, Astel­las ven­ture arms add cash to Avi­lar's 'AT­AC' mis­sion

The ven­ture arms of Sanofi and Astel­las have grown their in­vest­ment in Avi­lar Ther­a­peu­tics to help steer the biotech through a niche of the grow­ing pro­tein degra­da­tion field.

Med­ical Ex­cel­lence Cap­i­tal al­so joined the Big Phar­ma’s in­vest­ment teams, along with orig­i­nal in­vestor RA Cap­i­tal. The com­pa­ny orig­i­nal­ly an­nounced a $60 mil­lion com­mit­ment from RA Cap­i­tal in 2021, with the round now at $75 mil­lion, CEO Daniel Grau told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.